Back to results
US 2018/0000822 A1Published application
Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer
AssigneeThe University of Sheffield
InventorThomas Helleday
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.
Claims20
1-32. (canceled)
A method of treatment of cancer cells defective in homologous recombination (HR) in a human patient, the method comprising;
- administering to the patient a therapeutically effective amount of a compound which inhibits PARP-1.
Dependencies are inferred from the claim text.